MECHANICSBURG, Pa., Jan. 23, 2025 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM), will release the financial results for its fourth quarter and year ended December 31, 2024 on Thursday, February 20, 2025 after the market closes.
Select Medical will host a conference call regarding its fourth quarter and full year results, as well as its business outlook, on Friday, February 21, 2025, at 9:00am ET. The conference call will be a live webcast and can be accessed at via this Earnings Call Webcast Link or via link at Select Medical Holdings Corporation's website at www.selectmedicalholdings.com. A replay of the webcast will be available shortly after the call through the same link.
For listeners wishing to dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Select Medical Earnings Call Registration to obtain your dial-in number and unique passcode for the call.
Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States based on the number of facilities. Select Medical's reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, and the outpatient rehabilitation segment. As of December 31, 2024, Select Medical operated 104 critical illness recovery hospitals in 29 states, 35 rehabilitation hospitals in 14 states, and 1,914 outpatient rehabilitation clinics in 39 states and the District of Columbia. At December 31, 2024, Select Medical had operations in 41 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.
Investor inquiries:
Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$19.53 |
Daily Change: | 0.25 1.30 |
Daily Volume: | 261,820 |
Market Cap: | US$2.520B |
October 31, 2024 October 17, 2024 September 04, 2024 August 01, 2024 July 31, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load